Clinical Trials Logo

Infliximab clinical trials

View clinical trials related to Infliximab.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06051253 Recruiting - Crohn Disease Clinical Trials

TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease

Start date: November 1, 2023
Phase: Phase 4
Study type: Interventional

This study will compare the efficacy and safety of TDM (therapeutic drug monitoring)-based infliximab (CT-P13, RemsimaTM) intravenous therapy compared with the standard infliximab (RemsimaTM) intravenous therapy for patients with active perianal fistulzing Crohn's disease.

NCT ID: NCT05043870 Recruiting - Crohn Disease Clinical Trials

Combined Immunosuppression for Pediatric Crohn's Disease

Start date: October 10, 2022
Phase: Phase 4
Study type: Interventional

This is a randomized controlled trial to compare the efficacy and safety of infliximab and immunosuppressives therapy alone or in combination for pediatric Crohn's disease.

NCT ID: NCT04999228 Recruiting - Ulcerative Colitis Clinical Trials

Top Down Versus Step up in Pediatric Ulcerative Colitis

Start date: November 1, 2021
Phase: Phase 4
Study type: Interventional

Pediatric Ulcerative Colitis (UC) patients with moderate to severe disease activity at high risk of colectomy. Early use of biologic agents will likely be more effective. But there were no studies identified that compared a strategy of upfront biologic-based therapy versus gradual step-up therapy. In our study, newly diagnosed moderate to severe pediatric UC patients (6-18 years old) will be randomly divided into infliximab (IFX) treatment group (Top down group, TD) and corticosteroids (CS) treatment group (Step-up group, SU). Mucosal healing rate at week 12 will be compared between the two groups. The relapse rates and sustained durations of remission within one year will also be evaluated.

NCT ID: NCT01282528 Recruiting - Clinical trials for Rheumatoid Arthritis

Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis

ULTRA
Start date: September 2010
Phase: Phase 4
Study type: Interventional

To evaluate the predictive value of clinical, functional (HAQ), laboratory and US variables in relation to disease activity and radiographic outcome in patients with RA who start treatment with Remicade at 24 weeks.